Endocrine Abstracts

Diabetes mellitus (DM) is a disease that results from impairment of insulin synthesis/secretion or signaling. The glycemia of type 1 DM (DM1) patients is controlled by insulin replacement therapy, which chronically results in insulin resistance. We have shown that alloxan-induced diabetic rats present hypothyroidism, and that T3 treatment reduced the inflammatory state and hepatic glucose production and increased insulin sensitivity, improving glycemia control. Considering tha...

Multiple benign symmetric lipomatosis (Madelung’s disease, Launois–Bensaude syndrome) is significantly rare disease characterised by symmetrical focal deposition of adipose tissue in the neck, upper part of the arms, back, pelvis, and thigh. Although its etiology is uncertain, it has been associated with genetic factors, mitochondrial inheritance and alcoholism. Its pathogenesis seems to include a dysfunction of cAMP and levels of catecholamines in adipocytes. This c...

Introduction: Combination therapy using pegvisomant and cabergoline with first-generation long-acting somatostatin analogs (1GSSA) is a common procedure in acromegalic patients that are not fully controlled by surgery and 1GSSA. Pasireotide-LAR is a new multireceptor-targeted somatostatin receptor ligand that has superior efficacy over octreotide LAR to control GH and IGF1 levels. Little data is available about the efficacy and safety of pasireotide monotherapy in patients tre...

IntroductionMaturity Onset Diabetes of the Young (MODY) affects 1–2% of diabetic patients. Subtype 5 (HNF1β mutation) is rare (~1% of all MODY subtypes) and extra-pancreatic manifestations are often present (chronic kidney disease (CKD), liver disease and/or genitourinary malformations).AimTo report and review confirmed MODY 5 cases in an Endocrinology Department.Meth...

IntroductionVitamin B12 (vB12) deficiency has been associated with a plethora of hematologic, neurologic and metabolic abnormalities. In pregnant women, several studies have demonstrated an association with a greater maternal body mass index (BMI), maternal and offspring insulin resistance, gestational diabetes mellitus (GDM) and even later type 2 diabetes.Aim of the studyEvaluation of maternal and fetal outc...

IntroductionSevere hyperandrogenism is a warning sign in young women. Differential diagnosis includes neoplastic, non-neoplastic and iatrogenic causes. The association of hyperandrogenism and congenital or acquired portosystemic shunt (PSS) has been rarely described, with its pathophysiology being unclear.Case 1A 22 year-old woman with diagnosis of autoimmune hepatitis, portal hypertension and PSS since 15 ye...

Background: Ectopic ACTH secretion from metastatic acinic cell carcinoma (ACC) of the parotid gland is extremely rare. ACC is an uncommon, typically indolent, salivary gland neoplasm. Herein, we report a case of a high-grade ACC later diagnosed with Cushing’s syndrome (CS).Case presentation: A 60-year-old man presented with a laterocervical mass. Computed tomography (CT) documented a 39×38 mm mass on the parotid gland and homolateral cervical l...

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...

Introduction: Distinguishing between gestational diabetes and MODY (Maturity Onset Diabetes of the Young) during pregnancy is relevant for therapeutic approaches and potential maternal-fetal complications. However, performing genetic study for MODY in pregnant women is uncommon.Aim: To describe 2 cases in which the hypothesis of MODY was considered during pregnancy. Case 1: Woman, 35 years old, G1P0A1, BMI 25 kg/m2. At 5 weeks of gestation, sh...

Introduction and objectives: Anaplastic thyroid cancer (ATC) has a very low overall survival (OS) and progression free survival (PFS) due to fast growth and resistance to non-target therapies. A recent phase II study showed a dramatic increase in OS and PFS of BRAF V600E mutated ATC patients treated with Dabrafenib and Trametinib (DT). However as commonly reported in melanoma durable responses in ATC may be compromised by resistance mechanisms. Until now only a few ca...